drugset / Trial / NCT02038621

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

NCT02038621 ↗

Phase 2 Unknown 224 enrolled The Second People's Hospital of Sichuan
RandomizedParallel-groupOpen-labelTreatment

Summary

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)

Timeline

Start
2014-01
Primary completion
2016-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 —
Background Oxaliplatin Small molecule — —
Background Paclitaxel Small molecule — —

Indications